---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056886"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:45:15.328856+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q1 net loss widens to $35.6M; evorpacept B-NHL data shows 83% CRR

## Summary
- GAAP net loss $35.6M ($0.71/sh) vs $30.2M ($0.74/sh) in Q1 2023; non-GAAP loss $28.5M vs $23.8M.
- Cash & investments $184.5M as of Mar 31; subsequent ATM raised ~$26.2M net; runway into Q1 2026.
- Evorpacept + R2 in R/R B-NHL IST: ORR 94%, CRR 83% (historical R2 CRR 34%) in 20 patients.
- Upcoming milestones: ASPEN-07 data at ASCO June 2; ASPEN-06 top line July 2024; Phase 3 init Q4 2024.
- Appointed Allison Dillon, Ph.D., as Chief Business Officer.

## SEC filing metadata
- accession: 0000950170-24-056886
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/0000950170-24-056886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/alxo-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056886
- JSON: https://secwatch.observer/filing/0000950170-24-056886.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056886.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/0000950170-24-056886-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.